July 26th 2024
The CAR T-cell therapy UCART22 has been granted orphan drug designation and rare pediatric drug designation from the FDA for the treatment of acute lymphoblastic leukemia.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Chemotherapy Plus Inotuzuamb Ozogamicin Elicits Promising Responses in B-Cell ALL
July 21st 2023Utilizing the combination of inotuzuamb ozogamicin and low intensity chemotherapy, with or without blinatumoamab, showed promising results, but also an increase of patient deaths during remission.
Read More
Assessing and Monitoring Manifestations of Chronic GVHD
July 18th 2023Catherine J. Lee, MD, MS, associate professor of medicine in the Clinical Research Division at Fred Hutchinson Cancer Center in Seattle, Washington, led a live virtual discussion on how to treat patients with chronic graft-vs-host disease (GVHD) and how best to assess the extent of their disease.
Read More
NCCN Update Aids Clinicians in Managing Methotrexate Toxicities
June 27th 2023Updates to the NCCN guidelines will help clinicians treat their patients with acute lymphoblastic leukemia, B-cell lymphomas, pediatric acute lymphoblastic leukemia, and pediatric aggressive mature B-cell lymphomas on high-dose methotrexate.
Read More